It would be nice to have more products, but there is a lot of risk attached to that.
Also, generics don't mean 'the end'. Most people stick to the brands they know (Panadol, Band-Aid, Voltaren, Viagra etc. are all household names, but still brands), it just means a potential loss in some market share. At this stage Androgel has the most to lose, and provided Eli Lilly can continue marketing Axiron well, then the generics really shouldn't be too much of a fear.
Add to My Watchlist
What is My Watchlist?
